glp·helper
glphelper.com/zepbound/maine/portland
Dual GIP / GLP-1 receptor agonistFDA-approved November 2023Rx · Subcutaneous injection · Once weekly

Zepbound® providers &
prescriptions in Portland, ME

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Physicians near Portland, ME from the federal NPI registry. Ask each office whether it prescribes Zepbound.[9]

average Zepbound weight loss →trial-anchored estimate
city providers
25
as of today

Same molecule (tirzepatide): Tirzepatide in Portland, Mounjaro in Portland

Other GLP-1 medicines: Ozempic in Portland, Wegovy in Portland, Semaglutide in Portland

§ 02Provider directory: Maine
25 of 25 shown

Find a Zepbound provider in Portland.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Zepbound by Maine town, physicians per town
§ 03Getting Zepbound in Portland
25 providers · Portland, ME

How to get Zepbound in Portland.

25 GLP-1 prescribers and 7 local resource types are on record for Portland, plus 2 nearby towns in the directory.

Physicians in Portland
25 physicians
25 physicians from the federal NPI registry in Portland, most listed as Family Medicine (11), Internal Medicine (6) and Internal Medicine, Endocrinology, Diabetes & Metabolism (5). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are Lewiston (31 providers) and Bangor (26 providers).
Around the prescription in Portland
7 listed nearby
6 dietitians, 3 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Portland.
Medicaid (weight loss)
Diabetes only
As of April 2026, Maine Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Maine’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.

Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]

Bar chart of Zepbound dose strengths on the FDA label: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Zepbound comes in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceMultiple (per dose)
Active ingredient
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
November 2023
Approved use
Chronic weight management (adults with obesity, or overweight with a weight-related condition) and moderate to severe obstructive sleep apnea in adults with obesity
Off-label use
Type 2 diabetes (Mounjaro is the FDA-approved tirzepatide for diabetes)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Maine

Diagnosed diabetes reaches 9% of adults in Maine.

of Maine adults have obesity
33.2%
diagnosed diabetes
9%

Age-adjusted estimates for Maine, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossweight regain after stopping
§ 05Support around Zepbound in Portland
3 nutritionists

The prescription is one part. Here is the rest, in Portland.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Portland, ME, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Chelsea Fyrberg
NUTRITIONIST
Nutritionist · Education
535 Ocean Ave
Call 207-831-3200NPI 1336546738
Stephanie Greenfield, CNP, FNP
NUTRITIONIST
Nutritionist
10 Exchange St
Call 508-479-3228NPI 1922932813
Cami Smalley, MS
NUTRITIONIST
Nutritionist
34 Congress St Apt 1
Call 207-370-4886NPI 1427674340

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Foley's Fitness Center
FITNESS
4.9 on Google · 441 reviews
33 Haigis Pkwy
Website
South Portland Community Center
REC CENTER
4.6 on Google · 184 reviews
21 Nelson Rd
Website
Portland Sports Complex
REC CENTER
4.2 on Google · 134 reviews
512 Warren Ave
Website
Hustle and Flow
FITNESS
4.9 on Google · 108 reviews
155 Brackett St
Website
NXGen Fitness Center
FITNESS
4.8 on Google · 93 reviews
29 Pleasant Hill Rd
Website
Recon MMA - Boxing, Jiu-Jitsu, Muay Thai
FITNESS
4.9 on Google · 74 reviews
1067 Riverside St Unit 1
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (10 mg)
−19.5%
SURMOUNT-1, 72 wk[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Zepbound weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Zepbound side effects are stomach and gut effects.

In Zepbound's weight trials at 5 to 15 mg, the most common side effects were nausea (25 to 29%), diarrhea (19 to 23%), constipation (11 to 17%), and vomiting (8 to 13%). Most reports came during dose escalation and decreased over time.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
25 to 29%
mild
Most reports came during dose escalation and decreased over time
Diarrhea
19 to 23%
mild
More frequent during dose escalation
Vomiting
8 to 13%
mild
Reduced by slower titration
Constipation
11 to 17%
mild
Abdominal pain
9 to 10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Zepbound costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Eli Lilly self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Zepbound monthly cost by how you pay
Pharmacy retail (no insurance)$1,000 to $1,300per monthBrand-name retail average, May 2026[6]
LillyDirect self-pay, KwikPen or vial$299 to $699per monthKwikPen by dose: 2.5 mg $299, 5 mg $399, 7.5 mg $499, 10 to 15 mg $699. The $449 offer on 7.5 to 15 mg applies to the first purchase and to refills within 45 days. Vials start at $299
Commercial insurance (weight)Often deniedOn-label for obesity but frequently requires prior authorization
Medicare GLP-1 Bridge$50per monthKwikPen only, Jul 1, 2026 to Dec 31, 2027, Part D enrollees who meet weight and health criteria[5]
Manufacturer savings cardas low as $25per monthCommercial insurance with coverage only; eligibility limits apply
Find Zepbound providers in Portland

Physicians from the federal NPI registry. Ask each office whether it prescribes Zepbound.

Zepbound in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Zepbound.

Related GLP-1 research
§ 09Frequently asked: Zepbound in Maine

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]